Real-world evidence of switching P2Y12 receptor-inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry.

Background: Potent P2Y inhibitors are recommended for up to 12 months after percutaneous coronary intervention (PCI) in patients diagnosed with acute coronary syndrome (ACS). However, the prescription pattern is diverse in real world practice, which includes various switching between antiplatelet regimens. In this study, we analyzed the prescription patterns of prasugrel, and assessed the safety and effectiveness of P2Y12 inhibitors switching patterns in a real world registry of patients subjected to PCI after ACS.

Influence of donor moiety in ruthenium sensitizers on the properties of dye-sensitized solar cells.

Heteroleptic ruthenium complexes cis-[Ru(H2dcbpy)(L)(NCS)2], where H2dcbpy is 4,4'-dicarboxylic acid-2,2'-bipyridine and L is 4-(4-(N,N-di-(p-hexyloxyphenyl)-amino)styryl)-4'-methyl-2,2'-bipyridine (Rut-A) or 4-(4'-(3,6-dihexyloxycarbazole-9-yl)-styryl)-4'-methyl-2,2'-bipyridine (Rut-B), have been synthesized and characterized by NMR, UV-Vis spectroscopy, and cyclic voltammogram. The effect of different electron donors on the properties of dye-sensitized solar cells has been studied. The power conversion efficiency of DSSC based on Rut-B is 6.